「with us」の検索結果
13件：6～10件目を表示
-
pan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
pan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
rch 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. ...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307.pdf -
Ethical Products for Medical Professionals | Business Activities | About Senju | SENJU Pharmaceutical
nce of medical professionals active on the front lines of medicine. Their clinical data provides us with the invaluable insights that accelerate the progress of our basic research. Working in close co...
https://www.senju.co.jp/english/about/business/mp.html -
rch 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. ...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307_0.pdf